-
Seminars in oncology · Apr 2003
ReviewAntisense therapy directed to protein kinase C-alpha (Affinitak, LY900003/ISIS 3521): potential role in breast cancer.
- Debasish Roychowdhury and Michael Lahn.
- Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46225, USA.
- Semin. Oncol. 2003 Apr 1; 30 (2 Suppl 3): 30-3.
AbstractAs our understanding of the biology of cancer increases, the attempts to target specific molecules associated with the promotion of cancer are accelerating. One of the targets currently being studied as an important tumor-promoting factor is protein kinase C-alpha (PKC-alpha). To specifically block PKC-alpha, antisense oligonucleotides have been developed, including LY900003 (Affinitak, ISIS-3521; Eli Lilly and Company, Indianapolis, IN), which is currently in clinical development. Although its single-agent activity in breast cancer is modest, its potential role may be in concert with traditional chemotherapy. This is a review of the pharmacology and current status of the clinical development of LY900003 and its potential role in treating patients with breast cancer.Copyright 2003 Elsevier Inc. All rights reserved.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*,_underline_or**bold**. - Superscript can be denoted by
<sup>text</sup>and subscript<sub>text</sub>. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3., hyphens-or asterisks*. - Links can be included with:
[my link to pubmed](http://pubmed.com) - Images can be included with:
 - For footnotes use
[^1](This is a footnote.)inline. - Or use an inline reference
[^1]to refer to a longer footnote elseweher in the document[^1]: This is a long footnote..